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The management of bronchiolitis obliterans syndrome (BOS) after hematopoietic cell transplantation pre-
sents many challenges, both diagnostically and therapeutically. We developed a computed tomography (CT)
voxel-wise methodology termed parametric response mapping (PRM) that quantiﬁes normal parenchyma,
functional small airway disease (PRMfSAD), emphysema, and parenchymal disease as relative lung volumes.
We now investigate the use of PRM as an imaging biomarker in the diagnosis of BOS. PRM was applied to CT
data from 4 patient cohorts: acute infection (n ¼ 11), BOS at onset (n ¼ 34), BOS plus infection (n ¼ 9), and
age-matched, nontransplant control subjects (n ¼ 23). Pulmonary function tests and bronchoalveolar lavage
were used for group classiﬁcation. Mean values for PRMfSAD were signiﬁcantly greater in patients with BOS
(38%  2%) when compared with those with infection alone (17%  4%, P < .0001) and age-matched control
subjects (8.4%  1%, P < .0001). Patients with BOS had similar PRMfSAD proﬁles, whether a concurrent
infection was present or not. An optimal cut-point for PRMfSAD of 28% of the total lung volume was identiﬁed,
with values >28% highly indicative of BOS occurrence. PRM may provide a major advance in our ability to
identify the small airway obstruction that characterizes BOS, even in the presence of concurrent infection.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION condition [1e3]. The development of National Institutes of
Pulmonary complications, both infectious and noninfec-
tious, are a common cause of morbidity and mortality after
hematopoietic cell transplantation (HCT).Within this context,
bronchiolitis obliterans syndrome (BOS) remains particularly
problematic, characterized clinically by ﬁxed airﬂow ob-
struction of small airways and pathologically by progressive
circumferential ﬁbrosis of terminal bronchioles. BOS is
extremely heterogeneous in its presentation, due inpart to the
nonuniform diagnostic criteria historically used to deﬁne theedgments on page 1598.
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2014 American Society for Blood and Marrow
14.06.014Health consensus criteria (NIH-CC) over the past decade has
been amajor advance in our recognition and categorization of
the disorder [2,4]. NIH-CCedeﬁned clinical parameters for the
diagnosis of BOS depend on a combination of clinical and
radiographic ﬁndings, including diminished forced expiratory
volumes in 1 second (FEV1), evidence of air trapping on high-
resolution computed tomography (HRCT), the absence of
active pulmonary infection, and the presence of chronic graft-
versus-host disease in another organ.
Using the NIH-CC deﬁnition, the criteria for BOS are often
not met until a patient exhibits signiﬁcant airway obstruc-
tion, with FEV1 values typically less than 60% predicted at the
deﬁned onset [3,5]. Once present, the prognosis of affected
patients is poor, with 5-year overall survival < 20% [5].
Therapeutic options for BOS are minimal, with responses
measured as disease stabilization rather than functionalTransplantation.
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the development of irreversible airway changes, may po-
tentially lead to improvements in therapeutic responses and
overall survival.
The parametric response mapping (PRM) technique has
been developed at our center as a quantitative imaging
biomarker for the assessment of obstructive lung disease.
PRM is a voxel-based approach that provides detailed infor-
mation on disease phenotype otherwise unattainable by
conventional CT-based quantitativemeasures. Using biphasic
(inspiratory and expiratory) HRCT, PRM is able to determine
the severity, phenotype, and spatial heterogeneity of the
pulmonary pathology using a methodology distinct from
other CT-based measures [8e11]. PRM was ﬁrst demon-
strated on HRCT data from patients with chronic obstructive
pulmonary disease, allowing quantiﬁcation of the degree of
functional small airway disease (fSAD) and emphysematous
changes in relation to normal lung parenchyma [8]. Com-
monly used CT metrics for the diagnosis of lung disease have
historically used tissue volumetric summary statistics of lung
ﬁelds, including the mean lung density. PRM, however,
classiﬁes local variations in lung function based on a voxel-
by-voxel comparison of lung attenuation changes from
coregistered inspiratory and expiratory CT scans, providing
both global and localized evaluations of lung pathology.
We now report on the application of PRM to patients with
BOS after HCT, speciﬁcally adapted to quantify the relative
contribution of fSAD in affected individuals irrespective of
the presence of acute infection. A comparison of PRM in
patients with BOS, at the time of initial diagnosis of BOS
(based on NIH-CC) and during episodes of secondary infec-
tion, is now examined.
METHODS
Retrospective clinical data, pulmonary function analysis, and HRCT im-
ages at inspiration and expiration were obtained from 3 groups of HCT
recipients at the University of Michigan Medical Center: group 1, infection,
no BOS; group 2, BOS, no infection; and group 3, BOS, with infection. Group 1
patients were early post-HCT (<120 days), with an acute infectious pneu-
monitis and no clinical or radiographic features of BOS. Group 2 patients
were selected at the time of NIH-CCedeﬁned onset of BOS, without active
pulmonary infection. Group 3 patients previously met the NIH-CC for BOS
but now exhibited an infectious pneumonitis.
Bronchoalveolar lavage (BAL) studies, including BAL special stains, PCR
assays for viral pathogens, and cultures for bacteria, fungi, viruses, and
mycobacteria, were performed to establish the presence (or absence) of an
infectious pneumonitis in patients in all groups. Pulmonary function tests
(PFTs) including measurements of FEV1, forced vital capacity (FVC), FEV1/
FVC ratio, residual volume, and lung diffusion capacity were obtained, with
measurements expressed as percent predicted values. Modiﬁed NIH-CC
were required to establish the diagnosis of BOS, including a FEV1 < 75%
predicted, signs of obstructive airway disease (FEV1/FVC ratio <.7, residual
volume >120% predicted, or evidence of air trapping on HRCT), absence of
infection, and the presence of chronic graft-versus-host disease in another
organ [4]. NIH lung function scores were determined, based on published
methodology [4].
Bronchoscopy was performed within 14 days (group 1) or 28 days
(groups 2 and 3) from the deﬁnedHRCT. PFTswere performedwithin 28 days
of the HRCT in group 2 and 3 patients. Paired PFTs and HRCT were not
available in group 1 patients, given the early post-transplant time course of
this group. FEV1, FEV1/FVC, and lung diffusion capacity were acquired as part
of the study design and analyzed in this study. In addition, a single case from
group 2 was identiﬁed as having 5 interval CT examinations. Data were
analyzed and presented to demonstrate the use of PRM to monitor pulmo-
nary complications anddisease progression. All transplant subjects signed an
institutional review boardeapproved informed consent for data collection
and analysis.
Additional age-matched, nontransplant, healthy subjects (group 4) were
analyzed for this study to serve as negative control subjects (n ¼ 23). These
subjects, accrued as part of a separate clinical trial at the University Medical
Center Groningen (NORM Study, NCT00848406), were individuals>40 years
of age who did not smoke during the last year and had <.5 pack yearssmoking history. Pulmonary function measurements (FEV1 and FEV1/FVC)
were acquired in all age-matched control subjects.
Parametric Response Mapping
The PRM method consists of 3 key steps: image acquisition, image
processing, and voxel classiﬁcation (Figure 1) [8].
Image acquisition
InternalCTdata at theUniversityofMichiganwere obtainedaswhole lung
volumetric CT scans at full inspiration (total lung capacity) and incremental
scans at relaxed expiration (functional residual capacity) on GE scanners (GE
Healthcare, Little Chalfont, UK) and reconstructed using a bone reconstruction
kernel. Slice thicknesses were 1.25 mm for all scans, with slice numbers on
average around 220 for inspiration scans and around 15 for expiration scans.
All CT scans were linearly Hounsﬁeld unit (HU)-corrected based on aortic
blood (50 HU) and central air (1000 HU) as described previously [12].
NORM Study CT data (for control subjects) were obtained as whole lung
volumetric acquisitions both at full inspiration and forced expiration (re-
sidual volume) on a Somatom scanner (Siemens, Munich, Germany) with
1-mm slice thickness and a reconstruction index of .7 mm. A standard kernel
(B30f) was used for image reconstruction. HU values of aortic blood (37 HU)
and central air (995 HU) were determined to check for scanner drift on all
NORM data. All data were found to have negligible drift; as such, no HU
corrections were performed.
Image processing
Image processing consisted of lung parenchymal segmentation followed
by deformable volumetric registration, which spatially aligns the inspiration
scan to the expiration scan such that both share the same spatial geometry.
The lungs from expiratory CT scans acquired at the University of Michigan
were segmented from the surrounding anatomy (ie, bronchus, heart, and
chest wall) using in-house algorithms developed in a mathematical pro-
gramming language (Matlab, Natick, MA). User veriﬁcation and manual
corrections were applied as necessary. Whole lung volumetric inspiration
datawere registered to the interval expiration data, allowing presentation of
the PRMs. Inspiratory scans were coregistered to expiratory scans for all
subjects and time points. Image registration was performed using a cost
function of mutual information and thin-plate spline warping deformations
[13]. Upon completion of image registration, the images share the same
geometric space. Each voxel, the smallest unit of volume in a 3-dimensional
image data set, consisted of a pair of HU values: 1 HU value at inspiration
and 1 HU value at expiration. For reference, air and water attenuation values
are 1000 and 0 HU, respectively.
The NORM trial acquired whole lung volumetric CT scans at both
inspiration and expiration, with CT data processed by our group as described
above. One distinction between the CT scans from the NORM trial and CT
scans from group 1, 2, and 3 subjects was the direction of scan registration
(geometric alignment), given differences in spatial arrangements between
inspiratory and expiratory views. In the NORM Study, expiration scans were
registered (aligned) to the inspiration scans [8], whereas CT scans for group
1, 2, and 3 subjects did the converse, aligning the inspiratory scans with the
expiration scans.
Voxel classiﬁcation
Classiﬁcation of the voxels from attenuation maps into discrete zones
allows quantiﬁcation of normal lung parenchyma, fSAD, emphysema, and
parenchymal disease characteristic of infection (Figure 1, Table 1). Three
thresholds are used to classify individual voxels into 1 of 4 categories with
the following color codes: emphysema (red voxels), fSAD (yellow voxels),
normal parenchyma (green voxels), and parenchymal disease (purple vox-
els). Voxels with HU values less than e950 on the inspiration scan and at
least e856 on the expiration scan have been identiﬁed previously as having
a weak correlation to pulmonary function (ie, FEV1) [8]. As such, no analysis
was performed on this measure. In addition, parenchymal tissue with voxel
values above e500 HU on the inspiration scan were not analyzed in this
study. Global PRM measures were calculated by normalizing the sum of all
voxels within a classiﬁcation by the total lung volume, which include all
parenchymal voxels over the full range of HU. The nomenclature of these
measures for normal lung parenchyma, fSAD, emphysema, and parenchymal
disease were PRMNormal, PRMfSAD, PRMEmph, and PRMPD, respectively.
Thresholds of e950 HU and e856 HU on the inspiration and expiration
scans, respectively, were deﬁned as speciﬁed by the COPDGene study [14].
The upper limit on the inspiration CT (e810 HU) was determined using
inspiration CT scans from the age-matched control subjects (group 4;
n ¼ 23) obtained from the NORM Study. Brieﬂy, the CT lung density data
were normalized by taking their natural logarithm. A bi-Gaussian ﬁt was
performed on the normalized CT data and the 95% conﬁdence interval
(1.96  standard deviation) of the principle peak that resides in a range of
e1000 to e500 was determined.
Figure 1. Schematic diagram of the PRM workﬂow.
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Group comparisons were determined for PRM and PFT measures using
an analysis of variance controlling for multiple comparisons using a Bon-
ferroni post-hoc test. A receiver operating characteristic (ROC) analysis was
performed for correlation of PRMfSADwith subjects diagnosedwith BOS. Only
subjects from group 1 (infection alone; n ¼ 11) and group 2 (BOS alone;
n ¼ 34) were used in this analysis. A more rigorous evaluation of PRMfSAD as
an indicator of BOS was performed using a discriminant analysis with leave-
one out cross-validation using groups 1 and 2. The discriminant analysis was
used to generate a predictivemodel for classifying subjects in groups 1 and 2
into 2 predicted groups. An additional ROC analysis was then applied using
PRMfSAD as an independent variable and the new predicted dichotomized
variable to determine an optimal cut-off for indicating BOS. Results were
considered statistically signiﬁcant at the 2-sided 5% comparison-wise sig-
niﬁcance level (P < .05). All data are presented as the mean  SEM. All sta-
tistical computations were performed with a statistical software package
(IBM SPSS Statistics, v. 21, Armonk, NY).
RESULTS
CTand PFT datawere acquired from 77 patients, including
54 patients who underwent HCT at the University ofTable 1
Classiﬁcation Schema, Based on Attenuation Maps
PRMEmph PRMfSAD
Inspiration e1000  to < e950 HU e950  to < e810 H
Expiration e1000  to < e856 HU e1000  to < e857 HMichigan and 23 control (nontransplant) subjects (Table 2).
Group 1 subjects (infection, n ¼ 11) underwent CT a median
of 63 days (range, 19 to 109) post-HCT. Infections in group 1
subjects included aspergillus (n ¼ 5), rhizopus (n ¼ 2),
fusarium (n ¼ 1), cytomegalovirus (n ¼ 1),Moraxella (n ¼ 1),
herpes hominis virus 6 (n ¼ 1), and Pneumocystis jirovecii
(n ¼ 1), with multiple pathogens identiﬁed in 2 patients.
Group 2 subjects (BOS, no infection) were selected at the
time the NIH-CC for BOS were met (n ¼ 34), undergoing CT a
median of 638 days (range, 199 to 1545) post-HCT. Group 3
subjects (BOS þ infection) (n ¼ 9) all had previously met the
NIH-CC for BOS but now exhibited an infectious pneumo-
nitis, undergoing CT a median of 970 days (range, 259 to
3940) post-HCT. Infections in group 3 subjects included
aspergillus (n ¼ 5), Pseudomonas (n ¼ 2), and nontuberculi
Mycobacterium species (n ¼ 2). Infections in this group were
typically subacute in nature, without acute infectious
symptomatology (fevers, chest pain, productive cough).PRMPD PRMNormal
U e810  to < e500 HU e950  to < e810 HU
U e1000  to < e500 HU e856  to < e500 HU
Table 2
Demographics
Group 1
(Infection)
Group 2
(BOS)
Group 3
(BOS þ
Infection)
Control
Subjects
Total patients 11 34 9 23
Age, yr
Median 58 54 53 57
Range 38-68 12-69 30-69 44-73
Gender
Males/Females 10/1 16/18 3/6 16/7
Disease NA*
AML/MDS 3 21 4
ALL 1 5 0
Lymphomas 5 2 3
Myeloma 2 2 2
CML 0 4 0
Days post-transplant NA
Median 63 638 970
Range 19-109 199-1545 259-3940
PFTy
FVC (median %) NAz 72 64 111
FEV1 (median %) NA 46 38 119
Lung diffusion capacity
(median %)
NA 54 49 NA
NIH lung function scoresx
Median NA 8 9 NA
Range NA 3-12 5-12
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
drome; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous
leukemia.
* Control subjects were healthy nontransplant subjects, nonsmokers,
with no underlying malignancy.
y Values are expressed as percent predicted.
z PFTs were not obtained at the time of HRCT for group 1 patients.
x NIH lung function scores per Filipovich [4].
Figure 2. Pulmonary complications identiﬁed by PRM. Normal lung tissue is den
emphysematous changes red (PRMEmph), and parenchymal disease purple (PRMPD). PR
color coded to disease component). (A) Healthy age-matched, nontransplant control s
onset, 448 days post-HCT. No concurrent infection present. (D) Pseudomonas pneumo
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control subjects, with FVC and FEV1 values above 100% pre-
dicted in these subjects.
The ability of PRM to characterize pulmonary pathology is
demonstrated in representative axial PRM images from age-
matched control subjects (Figure 2A and 3) individuals with
pulmonary complications after HCT, including an acute in-
fectious pneumonitis (Figure 2B), BOS at NIH-CCedeﬁned
onset (Figure 2C), and BOS with concurrent infection
(Figure 2D). PRM classiﬁed voxels as parenchymal disease
(PRMPD, purple in Figure 2B,D) with relative volumes ap-
proximately 30% of the total lung volume in these ﬁgures.
Subjects diagnosed with BOS, irrespective of the presence of
infection, were identiﬁed as having extensive nonemphy-
sematous air trapping as indicated by PRMfSAD (yellow in
Figure 2C,D). Parenchyma in a healthy control subject was
identiﬁed as being normal by PRM (PRMNormal, green
Figure 2A).
PRM from the control subjects were similar to those
observed in our previously published work [8]. In contrast,
reduced levels of normal lung parenchyma (PRMNormal) were
noted for all 3 transplant groups (P < .0001) (Figure 3). Mean
PRMfSADwere increased in subjects with BOS, in both group 2
(38%  2%) and group 3 (35%  3%). The mean PRMfSAD for
group 2 and 3 subjects was signiﬁcantly higher than group 1
subjects (17%  4%, P < .01) and age-matched control sub-
jects (8.4%  1%, P < .0001). There was no signiﬁcant differ-
ence in mean PRMfSAD between subjects in groups 2 and 3,
P ¼ NS. Mean PRMPD values were 17%  2% in group 2 (BOS,
no infection) and 11%  2% in age-matched control subjects
(P < .001). Although the mean PRMPD was higher in group 1oted green (PRMNormal), functional small airway disease yellow (PRMfSAD),
MfSAD and PRMPD values are provided at the bottom of PRM images (values are
ubjects. (B) Fungal pneumonitis, 61 days post-HCT. (C) BOS at NIH-CCedeﬁned
nitis in a patient with previously documented BOS, now 447 days post-HCT.
Figure 3. Group comparisons in pulmonary function measures and PRM. Bar
plots are used to present the group differences observed in PRM measure-
ments, PRMNormal, PRMfSAD, and PRMPD. Statistical signiﬁcance was assessed at
P < .05 and denoted by an asterisk. Data are presented as means  SEM.
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was not signiﬁcant, P ¼ .08. There was also no signiﬁcant
difference in the level of PRMPD between group 2 and group 3
subjects, potentially due to the subacute nature of the in-
fections in the group 3 patients. PRMEmph, a measure for
severe emphysematous changes, was <5% for all 3 subject
groups. Signiﬁcant differences in mean PRMEmph levels were
only observed between group 1 and 2 patients, with mean
PRMEmph values of .3% and 4.0% respectively, P ¼ .04.
We analyzed the predictive potential of PRMfSAD in
identifying subjects with BOS (group 2; n ¼ 34) from thoseFigure 4. Onset and progression of BOS post-HCT in a single patient. (A) Representati
with axes time (years) and PRM relative lung volumes (%) at various time points poswith acute pulmonary infection (group 1; n ¼ 11). We ﬁrst
used a ROC analysis to correlate PRMfSAD with the likelihood
that an individual would have BOS. PRMfSAD was found to
signiﬁcantly identify BOS with an area under the curve of
.861 (P < .001) and 95% conﬁdence intervals of .743 and .979.
We next performed a discriminant analysis with leave-one
out cross-validation that provided a more rigorous test of
PRMfSAD as an indicator of BOS. Through the discriminant
analysis, we again found PRMfSAD to be a signiﬁcant predictor
of BOS with sensitivity and speciﬁcity of .76 and .72,
respectively (P< .0001). Of all cross-validated grouped cases,
75% were correctly classiﬁed. To determine an optimal cut-
off, a ROC analysis of PRMfSAD using the newly classiﬁed
data from our discriminant analysis generated an optimal
PRMfSAD cut-off of 28% of the total lung volume, with values
>28% indicative of BOS. This PRMfSAD cut-point (>28%)
remained a valid indicator of BOS, irrespective of the pres-
ence (or absence) of a concurrent infection.
Serial PRM Measurements
The potential ability of PRM to identify signiﬁcant fSAD in
patients, before fulﬁllment of the NIH-CC for BOS, is shown in
Figure 4. In this patient, PRM imaging from a HRCT obtained
1 year post-HCT revealed PRMfSAD of 41%, with 17% PRMPD.
The NIH-CC for BOS would not be fulﬁlled, however, until
nearly 3 years post-HCT. During this same period, PRMfSAD
levels continued to increase, peaking at 3 years post-HCT at
65%, with PRMNormal decreasing from 27% to 13% over the
same time period. The subject subsequently underwent a
lung allograft approximately 7 years post-HCT for manage-
ment of his end-stage lung disease. As anticipated, PRMNormalve PRM axial slices are provided at discrete time points after HCT. (B) Line plot
t-HCT.
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13% to 54% of the total lung volume (Figure 4).
DISCUSSION
Wedemonstrate the utility of PRM, a voxel-based imaging
technique applied to paired inspiratory and expiratory CT
lung scans, to serve as a diagnostic index of fSAD after HCT.
Elevated levels of PRMfSADwere present in patients with BOS,
even in the setting of concurrent pulmonary infection. An
optimal cut-point for PRMfSAD of 28% of the total lung volume
was identiﬁed, with values >28% highly indicative of BOS. In
addition, by retaining spatial information within the lung
parenchyma, PRM provides a uniﬁed methodology that can
simultaneously identify and quantify the extent of fSAD
within the lungs. Quantitative PRM measures can be tracked
temporally, providing real-time diagnostic information on
the progression of fSAD that could be acted on by the treating
physician.
BOS is currently deﬁned by NIH-CC in which obstructive
airway disease (by radiographic and spirometric parameters)
plus absence of active lung infection are required to establish
the diagnosis. The application of the NIH-CC can be chal-
lenging, given the frequent infectious complications that
affected patients often exhibit post-HCT. Recurrent infections
in this patient population hinder our diagnostic capabilities,
with patients oftenmeeting NIH-CC for BOS only after severe
airﬂow abnormalities are already present. This is an impor-
tant problem, because once a patient is diagnosed with BOS,
overall survival is poor, <20% at 5 years [15]. The ability of
PRM to identify signiﬁcant elevations in fSAD, even in the
setting of an active infection, may lead to earlier recognition
of BOS and subsequent treatment interventions.
The role of PRM as an imaging biomarker for detection of
BOS requires validation in larger case series and may ulti-
mately complement known diagnostic markers for disease.
A number of novel biomarkers for early BOS detection,
including serologic and BAL ﬂuid biomarkers, were recently
reported in lung allograft and HCT recipients, including the
glycoprotein YKL-40, hypoxia inducible-1a, and various
metalloproteinases [16e18]. In lung allograft recipients, BAL
ﬂuid levels of IL-15, IL-17, TNF-a, and a1-antitrypsin were
predictive of BOS development in one report [17], with
overexpression of IL-8, lung surfactant proteins A and D, and
BAL ﬂuid neutrophil levels predictive of BOS in other reports
[18,19]. Noninvasive biomarkers, including measurement of
fractional exhaled nitric oxide, may additionally serve a role
in early BOS detection [20]. Given the heterogeneity of the
disorder, with complexities in both diagnosis and manage-
ment, a panel of both invasive and noninvasive biomarkers
may be required for diagnosis and risk classiﬁcation of
patients.
The current study focuses on the application of PRM in
patients with BOS after HCT. The study was not designed to
examine PRM within speciﬁc infections or examine the role
of PRM in other noninfectious pneumonitis post-HCT, in-
cluding idiopathic pneumonia syndrome, restrictive lung
disease, and cryptogenic organizing pneumonia. Fungal
pathogens were the predominant pathogen in both group 1
(infection, no BOS) and group 3 (BOS, with infection) pa-
tients, with a paucity of bacterial (n ¼ 3) and viral pneu-
monitis (n ¼ 2) present within the study population. In
addition, the current study did not ﬁnd signiﬁcant differ-
ences in fSAD levels between group 2 (BOS, no infection) and
group 3 (BOS, with infection), both groups exhibiting >30%
mean PRMfSAD. This is an important ﬁnding to note, becauseincreased levels of fSAD were thus present in patients with
BOS, regardless if a concurrent infection were present or not.
BOS exhibits a wide spectrum of phenotypes, character-
ized by a lymphocytic bronchitis and small airway inﬂam-
mation early in the clinical course, with subsequent ﬁbrinous
obliteration of bronchiolar lumen developing later in the
disease [21,22]. The histologic changes are often heteroge-
neous in nature, with varying degrees of involvement within
segments of individual lobes. Correlation of lung histology
with PRM values was limited in the current trial, with sur-
gical lung or transbronchial biopsies performed in only 6 of
the 34 group 2 patients. The spatial information gathered by
PRM may ultimately help clinicians identify (and target)
optimal sites for biopsy and lavage during diagnostic bron-
choscopic procedures.
Although CT is widely used for diagnosis and staging of
various lung disorders, a lack of consensus has brought about
various acquisition protocols and reconstruction algorithms
between CT scanners. In general, the best clinical practice for
the use of CT in diagnosing BOS is to use a well-calibrated
HRCT and to apply consistent acquisition and reconstruc-
tion parameters. PRM may provide disparate results from
multiple time-point CT examinations that do not take pre-
cautionary measures to avoid inconsistencies in acquisition
and reconstruction parameters. Nevertheless, image post-
processing can be performed to minimize ﬂuctuations in HU
values between similar CT examinations (eg, acquired at full
inspiration, consistent lung histograms). We, and others, ﬁnd
that HU values can be corrected to minimize effects from
scanner drift [12,23]. This procedure for correcting datasets
allows the use of archival data in many cases. Even low-
resolution interval expiration scan data produce reliable
PRM results. Using a separate cohort of CT data, we deter-
mined that the insertion of gaps (maximum 10-mm gap) in
whole lung volumetric expiration CT data only generated
differences of 1.6% from the high-resolution (contiguous)
PRM analysis (unpublished results, JLB, BDR, CJG, 2014).
Nevertheless, HU-based measurements using widely spaced
axial slices have the potential to misrepresent disease
classiﬁcation, particularly when the disease is spatially
heterogeneous.
Other limitations in the current study must be addressed.
The ﬁrst is the retrospective nature of sample collection,
resulting in the use of varying CT protocols on an interpatient
basis. Despite the great care that was taken to minimize
intrapatient variability in CT protocols and reconstruction
algorithms, in some cases patient CT acquisitions and
reconstruction algorithms varied slightly. As described pre-
viously, additional analyses were performed to investigate
the sensitivity of PRM measurements to low-resolution in-
terval expiration CT scans and reconstruction algorithms. In
addition, we previously tested the effect of different regis-
tration directions on the PRM results. Again using a separate
cohort of whole lung volumetric inspiration and expiration
CT data, we found that registering to the expiration scans
overestimates the amount of PRMfSAD in absolute terms by
approximately 5% when compared with PRM results from
registrations to the inspiration scans (unpublished data, JLB,
BDR, CJG, 2014). Although beyond the scope of this study, a
more thorough analysis is necessary to fully ascertain the
limits of the PRM analytical approach.
This is the ﬁrst trial to investigate the role of PRM in char-
acterizing BOS post-HCT. Many questions remain. Is there a
more optimal PRMfSAD cut-point for identifying BOS, one with
a higher sensitivity and speciﬁcity than currently exhibited?
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spirometry, before any signiﬁcantdecline in FEV1 or FEV1/FVC?
Can a PRM signature for BOS be validated in amulticenter trial,
in which centers have applied varying CT acquisition tech-
niques? Does a PRM signature exist for other pulmonary
complications post-HCT, potentially differentiating infectious
from noninfectious pulmonary complications? Ultimately,
PRM requires testing in a multisite clinical trial consisting
of highly characterized subjects with detailed longitudinal
data collection, including spirometric measurements, to vali-
date this work in both BOS and other post-transplant lung
complications.
In conclusion, PRM provides a quantitative imaging
analysis for patients with BOS after HCT, with elevated levels
of fSAD present in affected patients. The ability for PRM to
both quantify and spatially deﬁne the severity of lung airway
disease in patients with BOS may serve as a major advance in
the diagnosis and management of this disorder.
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